JP2008508357A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508357A5 JP2008508357A5 JP2007524853A JP2007524853A JP2008508357A5 JP 2008508357 A5 JP2008508357 A5 JP 2008508357A5 JP 2007524853 A JP2007524853 A JP 2007524853A JP 2007524853 A JP2007524853 A JP 2007524853A JP 2008508357 A5 JP2008508357 A5 JP 2008508357A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- tetrahydro
- benzimidazol
- quinolinamine
- piperidinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 52
- 125000003342 alkenyl group Chemical group 0.000 claims description 32
- 125000000304 alkynyl group Chemical group 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 17
- 150000001412 amines Chemical class 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- -1 2-{[methyl (5,6,7,8-tetrahydro-8-quinolinyl) amino] methyl} -1H-benzimidazol-1-yl Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 38
- 125000000753 cycloalkyl group Chemical group 0.000 claims 38
- 150000003973 alkyl amines Chemical class 0.000 claims 14
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 14
- 125000001188 haloalkyl group Chemical group 0.000 claims 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 150000001540 azides Chemical class 0.000 claims 8
- 125000004450 alkenylene group Chemical group 0.000 claims 7
- 125000002947 alkylene group Chemical group 0.000 claims 7
- 125000004419 alkynylene group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000005724 cycloalkenylene group Chemical group 0.000 claims 7
- 125000002993 cycloalkylene group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000002883 imidazolyl group Chemical group 0.000 claims 7
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- VETGEHMWKIZMPG-UHFFFAOYSA-N n-methyl-n-[[1-[(1-methylpiperidin-3-yl)methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC1CCCN(C)C1 VETGEHMWKIZMPG-UHFFFAOYSA-N 0.000 claims 5
- QSKQVYGGIODIIN-BWKNWUBXSA-N (8s)-n-methyl-n-[[1-[[(3r)-1-propan-2-ylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1N(C(C)C)CCC[C@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@@H]1C2=NC=CC=C2CCC1 QSKQVYGGIODIIN-BWKNWUBXSA-N 0.000 claims 4
- SUVTXSXXZWCMHL-NVQXNPDNSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-(2-methylpropyl)piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1N(CC(C)C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@@H]1C2=NC=CC=C2CCC1 SUVTXSXXZWCMHL-NVQXNPDNSA-N 0.000 claims 4
- VETGEHMWKIZMPG-CVDCTZTESA-N (8s)-n-methyl-n-[[1-[[(3s)-1-methylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCN(C)C1 VETGEHMWKIZMPG-CVDCTZTESA-N 0.000 claims 4
- ASCHSOKJVZUWMP-UHFFFAOYSA-N n-[[1-(3-aminopropyl)benzimidazol-2-yl]methyl]-n-ethyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(CC)CC1=NC2=CC=CC=C2N1CCCN ASCHSOKJVZUWMP-UHFFFAOYSA-N 0.000 claims 4
- JEPDGRCNPREMJT-UHFFFAOYSA-N n-[[1-[3-(dimethylamino)propyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(CCCN(C)C)C(CN(C)C3C4=NC=CC=C4CCC3)=NC2=C1 JEPDGRCNPREMJT-UHFFFAOYSA-N 0.000 claims 4
- IBMXMPNDZLRVME-UHFFFAOYSA-N n-methyl-n-[[1-[(1-methylazetidin-3-yl)methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC1CN(C)C1 IBMXMPNDZLRVME-UHFFFAOYSA-N 0.000 claims 4
- NTSBJKADBVYMSM-UHFFFAOYSA-N n-methyl-n-[[1-[(1-methylpyrrolidin-3-yl)methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC1CCN(C)C1 NTSBJKADBVYMSM-UHFFFAOYSA-N 0.000 claims 4
- MFZFCJAAAVWRCZ-OFVILXPXSA-N (8s)-n-[[1-[[(3s)-1-methylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-n-propyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CCCN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCN(C)C1 MFZFCJAAAVWRCZ-OFVILXPXSA-N 0.000 claims 3
- OVVVPNSGDFVCAW-HOFKKMOUSA-N (8s)-n-[[1-[[(3s)-1-propan-2-ylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-n-propyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CCCN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCN(C(C)C)C1 OVVVPNSGDFVCAW-HOFKKMOUSA-N 0.000 claims 3
- VETGEHMWKIZMPG-XXBNENTESA-N (8s)-n-methyl-n-[[1-[[(3r)-1-methylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@@H]1CCCN(C)C1 VETGEHMWKIZMPG-XXBNENTESA-N 0.000 claims 3
- XHRXIYNWBWPAAC-GCJKJVERSA-N (8s)-n-methyl-n-[[1-[[(3r)-piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@@H]1CCCNC1 XHRXIYNWBWPAAC-GCJKJVERSA-N 0.000 claims 3
- GHZOBXUUQBAKHP-HOFKKMOUSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-(3-methylbutyl)piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1N(CCC(C)C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@@H]1C2=NC=CC=C2CCC1 GHZOBXUUQBAKHP-HOFKKMOUSA-N 0.000 claims 3
- QSKQVYGGIODIIN-OFVILXPXSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-propan-2-ylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1N(C(C)C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@@H]1C2=NC=CC=C2CCC1 QSKQVYGGIODIIN-OFVILXPXSA-N 0.000 claims 3
- XHRXIYNWBWPAAC-AVRDEDQJSA-N (8s)-n-methyl-n-[[1-[[(3s)-piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCNC1 XHRXIYNWBWPAAC-AVRDEDQJSA-N 0.000 claims 3
- OGKYHMHLZSDZND-RDPSFJRHSA-N 2-[(3s)-3-[[2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]benzimidazol-1-yl]methyl]piperidin-1-yl]ethanol Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCN(CCO)C1 OGKYHMHLZSDZND-RDPSFJRHSA-N 0.000 claims 3
- JSIVRGPWVYZZRY-RDPSFJRHSA-N 2-[[1-[[(3s)-1-methylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]ethanol Chemical compound C1N(C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(CCO)[C@@H]1C2=NC=CC=C2CCC1 JSIVRGPWVYZZRY-RDPSFJRHSA-N 0.000 claims 3
- USAIXVIEVCGFRQ-NVQXNPDNSA-N 2-[[1-[[(3s)-1-propan-2-ylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]ethanol Chemical compound C1N(C(C)C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(CCO)[C@@H]1C2=NC=CC=C2CCC1 USAIXVIEVCGFRQ-NVQXNPDNSA-N 0.000 claims 3
- ZGXWKJJTZYBTPX-OFVILXPXSA-N 3-[(3s)-3-[[2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]benzimidazol-1-yl]methyl]piperidin-1-yl]propan-1-ol Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCN(CCCO)C1 ZGXWKJJTZYBTPX-OFVILXPXSA-N 0.000 claims 3
- PXSYBAMOAXOVKV-OFVILXPXSA-N 3-[[1-[[(3s)-1-methylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]propan-1-ol Chemical compound C1N(C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(CCCO)[C@@H]1C2=NC=CC=C2CCC1 PXSYBAMOAXOVKV-OFVILXPXSA-N 0.000 claims 3
- HNPRTVLVYBDBAL-HOFKKMOUSA-N 3-[[1-[[(3s)-1-propan-2-ylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]propan-1-ol Chemical compound C1N(C(C)C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(CCCO)[C@@H]1C2=NC=CC=C2CCC1 HNPRTVLVYBDBAL-HOFKKMOUSA-N 0.000 claims 3
- HEPWOFBXMDSUEO-UHFFFAOYSA-N n-[[1-(3-aminopropyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(CCCN)C(CNC3C4=NC=CC=C4CCC3)=NC2=C1 HEPWOFBXMDSUEO-UHFFFAOYSA-N 0.000 claims 3
- FFROZRURSWKTSQ-UHFFFAOYSA-N n-methyl-n-[[1-(1-methylpiperidin-4-yl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1C1CCN(C)CC1 FFROZRURSWKTSQ-UHFFFAOYSA-N 0.000 claims 3
- SIQJINIEOSWWSC-UHFFFAOYSA-N n-methyl-n-[[1-(piperidin-4-ylmethyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC1CCNCC1 SIQJINIEOSWWSC-UHFFFAOYSA-N 0.000 claims 3
- 238000006268 reductive amination reaction Methods 0.000 claims 3
- MSEIVERZUJBQCE-AVRDEDQJSA-N (3r)-3-[[2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]benzimidazol-1-yl]methyl]piperidine-1-carboximidamide Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCN(C(N)=N)C1 MSEIVERZUJBQCE-AVRDEDQJSA-N 0.000 claims 2
- CPNLVENHHDENTG-CVDCTZTESA-N (3r)-n'-cyano-3-[[2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]benzimidazol-1-yl]methyl]piperidine-1-carboximidamide Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCN(C(N)=NC#N)C1 CPNLVENHHDENTG-CVDCTZTESA-N 0.000 claims 2
- QSKQVYGGIODIIN-PXDATVDWSA-N (8r)-n-methyl-n-[[1-[[(3r)-1-propan-2-ylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1N(C(C)C)CCC[C@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@H]1C2=NC=CC=C2CCC1 QSKQVYGGIODIIN-PXDATVDWSA-N 0.000 claims 2
- GHZOBXUUQBAKHP-WNCULLNHSA-N (8r)-n-methyl-n-[[1-[[(3s)-1-(3-methylbutyl)piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1N(CCC(C)C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@H]1C2=NC=CC=C2CCC1 GHZOBXUUQBAKHP-WNCULLNHSA-N 0.000 claims 2
- QSKQVYGGIODIIN-SQJMNOBHSA-N (8r)-n-methyl-n-[[1-[[(3s)-1-propan-2-ylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1N(C(C)C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@H]1C2=NC=CC=C2CCC1 QSKQVYGGIODIIN-SQJMNOBHSA-N 0.000 claims 2
- BTACNCKTZXBULU-CUBQBAPOSA-N (8s)-n-(2-methylpropyl)-n-[[1-[[(3s)-1-propan-2-ylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CC(C)CN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCN(C(C)C)C1 BTACNCKTZXBULU-CUBQBAPOSA-N 0.000 claims 2
- UPBCAKKETXMWBJ-IBGZPJMESA-N (8s)-n-[[1-(3-aminopropyl)benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2[C@H]1N(C)CC1=NC2=CC=CC=C2N1CCCN UPBCAKKETXMWBJ-IBGZPJMESA-N 0.000 claims 2
- CGSWUZHHBXFQBH-OFVILXPXSA-N (8s)-n-[[1-[[(3s)-1-(1h-imidazol-2-ylmethyl)piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C([C@@H](C1)CN2C3=CC=CC=C3N=C2CN(C)[C@@H]2C3=NC=CC=C3CCC2)CCN1CC1=NC=CN1 CGSWUZHHBXFQBH-OFVILXPXSA-N 0.000 claims 2
- ITBGCVICESLOAL-NVQXNPDNSA-N (8s)-n-[[1-[[(3s)-1-[2-(dimethylamino)ethyl]piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1N(CCN(C)C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@@H]1C2=NC=CC=C2CCC1 ITBGCVICESLOAL-NVQXNPDNSA-N 0.000 claims 2
- QIDLXLXPSJTZEG-CUBQBAPOSA-N (8s)-n-[[1-[[(3s)-1-[3-(dimethylamino)-2,2-dimethylpropyl]piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1N(CC(C)(C)CN(C)C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@@H]1C2=NC=CC=C2CCC1 QIDLXLXPSJTZEG-CUBQBAPOSA-N 0.000 claims 2
- PTEDXWWFEGUZEY-SVEHJYQDSA-N (8s)-n-[[1-[[(3s)-1-benzylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C([C@@H](C1)CN2C3=CC=CC=C3N=C2CN(C)[C@@H]2C3=NC=CC=C3CCC2)CCN1CC1=CC=CC=C1 PTEDXWWFEGUZEY-SVEHJYQDSA-N 0.000 claims 2
- GHZOBXUUQBAKHP-KCWPFWIISA-N (8s)-n-methyl-n-[[1-[[(3r)-1-(3-methylbutyl)piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1N(CCC(C)C)CCC[C@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@@H]1C2=NC=CC=C2CCC1 GHZOBXUUQBAKHP-KCWPFWIISA-N 0.000 claims 2
- KNNLCWNQAVHYHR-FIPFOOKPSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-(pyridin-2-ylmethyl)piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C([C@@H](C1)CN2C3=CC=CC=C3N=C2CN(C)[C@@H]2C3=NC=CC=C3CCC2)CCN1CC1=CC=CC=N1 KNNLCWNQAVHYHR-FIPFOOKPSA-N 0.000 claims 2
- AZXYEYLEAPSWTK-CUBQBAPOSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-(pyridin-3-ylmethyl)piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C([C@@H](C1)CN2C3=CC=CC=C3N=C2CN(C)[C@@H]2C3=NC=CC=C3CCC2)CCN1CC1=CC=CN=C1 AZXYEYLEAPSWTK-CUBQBAPOSA-N 0.000 claims 2
- KSHLOXFXDIORRL-CUBQBAPOSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-(pyridin-4-ylmethyl)piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C([C@@H](C1)CN2C3=CC=CC=C3N=C2CN(C)[C@@H]2C3=NC=CC=C3CCC2)CCN1CC1=CC=NC=C1 KSHLOXFXDIORRL-CUBQBAPOSA-N 0.000 claims 2
- CMSCMGVPSNOUIM-CUNXSJBXSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-(thiophen-2-ylmethyl)piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C([C@@H](C1)CN2C3=CC=CC=C3N=C2CN(C)[C@@H]2C3=NC=CC=C3CCC2)CCN1CC1=CC=CS1 CMSCMGVPSNOUIM-CUNXSJBXSA-N 0.000 claims 2
- ICASOSHOAZDLCQ-CKOJHNACSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-[[(2r)-1-methylpyrrolidin-2-yl]methyl]piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C([C@@H](C1)CN2C3=CC=CC=C3N=C2CN(C)[C@@H]2C3=NC=CC=C3CCC2)CCN1C[C@H]1CCCN1C ICASOSHOAZDLCQ-CKOJHNACSA-N 0.000 claims 2
- ICASOSHOAZDLCQ-AGJHTDJMSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-[[(2s)-1-methylpyrrolidin-2-yl]methyl]piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C([C@@H](C1)CN2C3=CC=CC=C3N=C2CN(C)[C@@H]2C3=NC=CC=C3CCC2)CCN1C[C@@H]1CCCN1C ICASOSHOAZDLCQ-AGJHTDJMSA-N 0.000 claims 2
- RYNSAIDPKSCSKJ-XXJPWZBZSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-[[(2s)-1-propan-2-ylpyrrolidin-2-yl]methyl]piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CC(C)N1CCC[C@H]1CN1C[C@@H](CN2C3=CC=CC=C3N=C2CN(C)[C@@H]2C3=NC=CC=C3CCC2)CCC1 RYNSAIDPKSCSKJ-XXJPWZBZSA-N 0.000 claims 2
- LILSBXJJIIFDGR-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinolin-8-amine Chemical compound C1CCNC2=C1C=CC=C2N LILSBXJJIIFDGR-UHFFFAOYSA-N 0.000 claims 2
- RJUSPAJEXRXMFD-UHFFFAOYSA-N 2-[2,2-dimethyl-3-[2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]benzimidazol-1-yl]propyl]guanidine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC(C)(C)CNC(N)=N RJUSPAJEXRXMFD-UHFFFAOYSA-N 0.000 claims 2
- PTJSFJFYRHYIAG-UHFFFAOYSA-N 2-[2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]benzimidazol-1-yl]-n-(pyridin-3-ylmethyl)acetamide Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC(=O)NCC1=CC=CN=C1 PTJSFJFYRHYIAG-UHFFFAOYSA-N 0.000 claims 2
- XVBHJNYVOUOSQU-UHFFFAOYSA-N 2-[3-[2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]benzimidazol-1-yl]propyl]guanidine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCCN=C(N)N XVBHJNYVOUOSQU-UHFFFAOYSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- AMJRGYWDPGQUFD-SREVYHEPSA-N n-[[1-[(z)-4-(dimethylamino)but-2-enyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(C\C=C/CN(C)C)C(CN(C)C3C4=NC=CC=C4CCC3)=NC2=C1 AMJRGYWDPGQUFD-SREVYHEPSA-N 0.000 claims 2
- WGGZMASUPJMNOJ-UHFFFAOYSA-N n-[[1-[3-(dimethylamino)-2,2-dimethylpropyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(CC(C)(C)CN(C)C)C(CN(C)C3C4=NC=CC=C4CCC3)=NC2=C1 WGGZMASUPJMNOJ-UHFFFAOYSA-N 0.000 claims 2
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 claims 2
- CEZDJMFFDIZREC-UHFFFAOYSA-N n-methyl-n-[[1-(2-piperidin-2-ylethyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCC1CCCCN1 CEZDJMFFDIZREC-UHFFFAOYSA-N 0.000 claims 2
- LJLXFECAEZYHOF-UHFFFAOYSA-N n-methyl-n-[[1-(pyrrolidin-3-ylmethyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC1CCNC1 LJLXFECAEZYHOF-UHFFFAOYSA-N 0.000 claims 2
- SMYBYHLPPUNRDO-UHFFFAOYSA-N n-methyl-n-[[1-[3-(3-methylbutylamino)propyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(CCCNCCC(C)C)C(CN(C)C3C4=NC=CC=C4CCC3)=NC2=C1 SMYBYHLPPUNRDO-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- MSEIVERZUJBQCE-PGRDOPGGSA-N (3r)-3-[[2-[[methyl-[(8r)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]benzimidazol-1-yl]methyl]piperidine-1-carboximidamide Chemical compound CN([C@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCN(C(N)=N)C1 MSEIVERZUJBQCE-PGRDOPGGSA-N 0.000 claims 1
- NTXFYIUIGQCZRF-OFVILXPXSA-N (3r)-n'-cyano-n,n-dimethyl-3-[[2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]benzimidazol-1-yl]methyl]piperidine-1-carboximidamide Chemical compound C1N(C(=NC#N)N(C)C)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@@H]1C2=NC=CC=C2CCC1 NTXFYIUIGQCZRF-OFVILXPXSA-N 0.000 claims 1
- DDMQPPLQWUBLIP-NVQXNPDNSA-N (3r)-n-cyano-3-[[2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]benzimidazol-1-yl]methyl]-n'-propylpiperidine-1-carboximidamide Chemical compound C1N(C(NC#N)=NCCC)CCC[C@@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@@H]1C2=NC=CC=C2CCC1 DDMQPPLQWUBLIP-NVQXNPDNSA-N 0.000 claims 1
- MSEIVERZUJBQCE-XMSQKQJNSA-N (3s)-3-[[2-[[methyl-[(8r)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]benzimidazol-1-yl]methyl]piperidine-1-carboximidamide Chemical compound CN([C@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@@H]1CCCN(C(N)=N)C1 MSEIVERZUJBQCE-XMSQKQJNSA-N 0.000 claims 1
- MSEIVERZUJBQCE-GCJKJVERSA-N (3s)-3-[[2-[[methyl-[(8s)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]benzimidazol-1-yl]methyl]piperidine-1-carboximidamide Chemical compound CN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@@H]1CCCN(C(N)=N)C1 MSEIVERZUJBQCE-GCJKJVERSA-N 0.000 claims 1
- KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 claims 1
- GHZOBXUUQBAKHP-YIXXDRMTSA-N (8r)-n-methyl-n-[[1-[[(3r)-1-(3-methylbutyl)piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1N(CCC(C)C)CCC[C@H]1CN1C2=CC=CC=C2N=C1CN(C)[C@H]1C2=NC=CC=C2CCC1 GHZOBXUUQBAKHP-YIXXDRMTSA-N 0.000 claims 1
- VETGEHMWKIZMPG-AUSIDOKSSA-N (8r)-n-methyl-n-[[1-[[(3r)-1-methylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@@H]1CCCN(C)C1 VETGEHMWKIZMPG-AUSIDOKSSA-N 0.000 claims 1
- VETGEHMWKIZMPG-WMZHIEFXSA-N (8r)-n-methyl-n-[[1-[[(3s)-1-methylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN([C@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCN(C)C1 VETGEHMWKIZMPG-WMZHIEFXSA-N 0.000 claims 1
- JEPDGRCNPREMJT-NRFANRHFSA-N (8s)-n-[[1-[3-(dimethylamino)propyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(CCCN(C)C)C(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=NC2=C1 JEPDGRCNPREMJT-NRFANRHFSA-N 0.000 claims 1
- PYOBOTPXYSPLKA-NVQXNPDNSA-N (8s)-n-[[1-[[(3s)-1-methylpiperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-n-(2-methylpropyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CC(C)CN([C@@H]1C2=NC=CC=C2CCC1)CC1=NC2=CC=CC=C2N1C[C@H]1CCCN(C)C1 PYOBOTPXYSPLKA-NVQXNPDNSA-N 0.000 claims 1
- HFOOXVONEVRLTM-QHCPKHFHSA-N (8s)-n-methyl-n-[[1-[3-(2-methylpropylamino)propyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(CCCNCC(C)C)C(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=NC2=C1 HFOOXVONEVRLTM-QHCPKHFHSA-N 0.000 claims 1
- VTFGCUIYMIFCFL-QFIPXVFZSA-N (8s)-n-methyl-n-[[1-[3-(propan-2-ylamino)propyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(CCCNC(C)C)C(CN(C)[C@@H]3C4=NC=CC=C4CCC3)=NC2=C1 VTFGCUIYMIFCFL-QFIPXVFZSA-N 0.000 claims 1
- JRXTWPLHXHGEEV-OFVILXPXSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-(1,3-thiazol-2-ylmethyl)piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C([C@@H](C1)CN2C3=CC=CC=C3N=C2CN(C)[C@@H]2C3=NC=CC=C3CCC2)CCN1CC1=NC=CS1 JRXTWPLHXHGEEV-OFVILXPXSA-N 0.000 claims 1
- RENDHKOGMOAKFH-FIPFOOKPSA-N (8s)-n-methyl-n-[[1-[[(3s)-1-[(1-methylpyrrol-2-yl)methyl]piperidin-3-yl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C([C@@H](C1)CN2C3=CC=CC=C3N=C2CN(C)[C@@H]2C3=NC=CC=C3CCC2)CCN1CC1=CC=CN1C RENDHKOGMOAKFH-FIPFOOKPSA-N 0.000 claims 1
- QWNUZIVMFONRKQ-UHFFFAOYSA-N 2-[2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]benzimidazol-1-yl]-n-(pyridin-4-ylmethyl)acetamide Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC(=O)NCC1=CC=NC=C1 QWNUZIVMFONRKQ-UHFFFAOYSA-N 0.000 claims 1
- VDNGVRIFOSTRQK-JDVJWJCPSA-N C1C[C@@H](N(C)C)CC[C@@H]1N1C2=CC=CC=C2N=C1CN(C)C1C2=NC=CC=C2CCC1 Chemical compound C1C[C@@H](N(C)C)CC[C@@H]1N1C2=CC=CC=C2N=C1CN(C)C1C2=NC=CC=C2CCC1 VDNGVRIFOSTRQK-JDVJWJCPSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- OCODMMOTZUFEQM-UHFFFAOYSA-N n-(2-aminoethyl)-2-[2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]benzimidazol-1-yl]acetamide Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC(=O)NCCN OCODMMOTZUFEQM-UHFFFAOYSA-N 0.000 claims 1
- MSJYCFPYFXRWOZ-UHFFFAOYSA-N n-(3-aminopropyl)-2-[2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]benzimidazol-1-yl]acetamide Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC(=O)NCCCN MSJYCFPYFXRWOZ-UHFFFAOYSA-N 0.000 claims 1
- MNVTWQUGUAKXKJ-UHFFFAOYSA-N n-[3-[2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]benzimidazol-1-yl]propyl]benzenesulfonamide Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCCNS(=O)(=O)C1=CC=CC=C1 MNVTWQUGUAKXKJ-UHFFFAOYSA-N 0.000 claims 1
- ZQVYUNVTADQXEW-UHFFFAOYSA-N n-[3-[2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]benzimidazol-1-yl]propyl]methanesulfonamide Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCCNS(C)(=O)=O ZQVYUNVTADQXEW-UHFFFAOYSA-N 0.000 claims 1
- WRSMRWFCNLYBGI-UHFFFAOYSA-N n-[4-[2-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]benzimidazol-1-yl]butyl]methanesulfonamide Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCCCNS(C)(=O)=O WRSMRWFCNLYBGI-UHFFFAOYSA-N 0.000 claims 1
- OGNGDPBBSWNLRN-UHFFFAOYSA-N n-[[1-(2-aminoethyl)benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCN OGNGDPBBSWNLRN-UHFFFAOYSA-N 0.000 claims 1
- NGHDXXSNCGEEMH-UHFFFAOYSA-N n-[[1-(3-aminopropyl)benzimidazol-2-yl]methyl]-n-(2-phenylethyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound N=1C2=CC=CC=C2N(CCCN)C=1CN(C1C2=NC=CC=C2CCC1)CCC1=CC=CC=C1 NGHDXXSNCGEEMH-UHFFFAOYSA-N 0.000 claims 1
- ZITGEMFBPHRZST-UHFFFAOYSA-N n-[[1-(3-aminopropyl)benzimidazol-2-yl]methyl]-n-(3-methylbutyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(CCC(C)C)CC1=NC2=CC=CC=C2N1CCCN ZITGEMFBPHRZST-UHFFFAOYSA-N 0.000 claims 1
- VUVIURYYVFNMDW-UHFFFAOYSA-N n-[[1-(3-aminopropyl)benzimidazol-2-yl]methyl]-n-benzyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound N=1C2=CC=CC=C2N(CCCN)C=1CN(C1C2=NC=CC=C2CCC1)CC1=CC=CC=C1 VUVIURYYVFNMDW-UHFFFAOYSA-N 0.000 claims 1
- UPBCAKKETXMWBJ-UHFFFAOYSA-N n-[[1-(3-aminopropyl)benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCCN UPBCAKKETXMWBJ-UHFFFAOYSA-N 0.000 claims 1
- HVKJPDOKVCUJIJ-UHFFFAOYSA-N n-[[1-(4-aminobutyl)benzimidazol-2-yl]methyl]-n-(2-phenylethyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound N=1C2=CC=CC=C2N(CCCCN)C=1CN(C1C2=NC=CC=C2CCC1)CCC1=CC=CC=C1 HVKJPDOKVCUJIJ-UHFFFAOYSA-N 0.000 claims 1
- VHPUCPSKTKDFDJ-UHFFFAOYSA-N n-[[1-(4-aminobutyl)benzimidazol-2-yl]methyl]-n-(3-methylbutyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(CCC(C)C)CC1=NC2=CC=CC=C2N1CCCCN VHPUCPSKTKDFDJ-UHFFFAOYSA-N 0.000 claims 1
- IDNVDBGEDKEVOV-UHFFFAOYSA-N n-[[1-(4-aminobutyl)benzimidazol-2-yl]methyl]-n-benzyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound N=1C2=CC=CC=C2N(CCCCN)C=1CN(C1C2=NC=CC=C2CCC1)CC1=CC=CC=C1 IDNVDBGEDKEVOV-UHFFFAOYSA-N 0.000 claims 1
- IDGSHCFMEWBTLX-UHFFFAOYSA-N n-[[1-(4-aminobutyl)benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCCCN IDGSHCFMEWBTLX-UHFFFAOYSA-N 0.000 claims 1
- OLDOFIFASUPIHM-SNAWJCMRSA-N n-[[1-[(e)-4-aminobut-2-enyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1C\C=C\CN OLDOFIFASUPIHM-SNAWJCMRSA-N 0.000 claims 1
- PSYKRCLDLQFSLB-UHFFFAOYSA-N n-[[1-[2,2-dimethyl-3-(3-methylbutylamino)propyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(CC(C)(C)CNCCC(C)C)C(CN(C)C3C4=NC=CC=C4CCC3)=NC2=C1 PSYKRCLDLQFSLB-UHFFFAOYSA-N 0.000 claims 1
- ZZMDSBMRFLQCAG-UHFFFAOYSA-N n-[[1-[2-[(dimethylamino)methyl]phenyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(C)CC1=CC=CC=C1N1C2=CC=CC=C2N=C1CN(C)C1C2=NC=CC=C2CCC1 ZZMDSBMRFLQCAG-UHFFFAOYSA-N 0.000 claims 1
- VHJWGEAEFAXLKK-UHFFFAOYSA-N n-[[1-[3-(dimethylamino)-2,2-dimethylpropyl]benzimidazol-2-yl]methyl]-n-(3-methylbutyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(CCC(C)C)CC1=NC2=CC=CC=C2N1CC(C)(C)CN(C)C VHJWGEAEFAXLKK-UHFFFAOYSA-N 0.000 claims 1
- UXUNSEQEZHBBCW-UHFFFAOYSA-N n-[[1-[3-(dimethylamino)propyl]imidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(C)CCCN1C=CN=C1CN(C)C1C2=NC=CC=C2CCC1 UXUNSEQEZHBBCW-UHFFFAOYSA-N 0.000 claims 1
- QFRHHIGNWWYNCW-UHFFFAOYSA-N n-[[1-[4-(dimethylamino)but-2-ynyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(CC#CCN(C)C)C(CN(C)C3C4=NC=CC=C4CCC3)=NC2=C1 QFRHHIGNWWYNCW-UHFFFAOYSA-N 0.000 claims 1
- BCSHSAWXUPAQRK-UHFFFAOYSA-N n-[[1-[4-[(dimethylamino)methyl]phenyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC(CN(C)C)=CC=C1N1C2=CC=CC=C2N=C1CN(C)C1C2=NC=CC=C2CCC1 BCSHSAWXUPAQRK-UHFFFAOYSA-N 0.000 claims 1
- AULWXDOLNIUIHM-UHFFFAOYSA-N n-[[1-[5-(dimethylamino)pentyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(CCCCCN(C)C)C(CN(C)C3C4=NC=CC=C4CCC3)=NC2=C1 AULWXDOLNIUIHM-UHFFFAOYSA-N 0.000 claims 1
- JKMACIYBSLRYFG-UHFFFAOYSA-N n-[[1-[6-(dimethylamino)hexyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CC=C2N(CCCCCCN(C)C)C(CN(C)C3C4=NC=CC=C4CCC3)=NC2=C1 JKMACIYBSLRYFG-UHFFFAOYSA-N 0.000 claims 1
- UNDNNIKYHXHKQM-UHFFFAOYSA-N n-[[1-[[2-[(dimethylamino)methyl]phenyl]methyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(C)CC1=CC=CC=C1CN1C2=CC=CC=C2N=C1CN(C)C1C2=NC=CC=C2CCC1 UNDNNIKYHXHKQM-UHFFFAOYSA-N 0.000 claims 1
- ZKKGGXQUXYNJGB-UHFFFAOYSA-N n-[[1-[[3-[(dimethylamino)methyl]phenyl]methyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(C)CC1=CC=CC(CN2C3=CC=CC=C3N=C2CN(C)C2C3=NC=CC=C3CCC2)=C1 ZKKGGXQUXYNJGB-UHFFFAOYSA-N 0.000 claims 1
- BBOCVTVNQPABFO-UHFFFAOYSA-N n-[[1-[[4-(aminomethyl)phenyl]methyl]benzimidazol-2-yl]methyl]-n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC1=CC=C(CN)C=C1 BBOCVTVNQPABFO-UHFFFAOYSA-N 0.000 claims 1
- ASUXLRCDSIRLGL-UHFFFAOYSA-N n-methyl-n-[(1-piperidin-4-ylbenzimidazol-2-yl)methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1C1CCNCC1 ASUXLRCDSIRLGL-UHFFFAOYSA-N 0.000 claims 1
- CRSPNDQKCCZUMP-UHFFFAOYSA-N n-methyl-n-[[1-(2-morpholin-4-ylethyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCN1CCOCC1 CRSPNDQKCCZUMP-UHFFFAOYSA-N 0.000 claims 1
- CGEYSKSKPCRPDK-UHFFFAOYSA-N n-methyl-n-[[1-(2-piperidin-1-ylethyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCN1CCCCC1 CGEYSKSKPCRPDK-UHFFFAOYSA-N 0.000 claims 1
- UORGAJVOEKJXAA-UHFFFAOYSA-N n-methyl-n-[[1-(2-pyridin-2-ylethyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCC1=CC=CC=N1 UORGAJVOEKJXAA-UHFFFAOYSA-N 0.000 claims 1
- BCMJGAIFNJHUGN-UHFFFAOYSA-N n-methyl-n-[[1-(2-pyridin-3-ylethyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCC1=CC=CN=C1 BCMJGAIFNJHUGN-UHFFFAOYSA-N 0.000 claims 1
- WLIBRESIFPMSPY-UHFFFAOYSA-N n-methyl-n-[[1-(3-morpholin-4-ylpropyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCCN1CCOCC1 WLIBRESIFPMSPY-UHFFFAOYSA-N 0.000 claims 1
- DNSXUYXUPGAKTI-UHFFFAOYSA-N n-methyl-n-[[1-(pyridin-2-ylmethyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC1=CC=CC=N1 DNSXUYXUPGAKTI-UHFFFAOYSA-N 0.000 claims 1
- OQMAUHRSKCHLHU-UHFFFAOYSA-N n-methyl-n-[[1-(pyridin-3-ylmethyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC1=CC=CN=C1 OQMAUHRSKCHLHU-UHFFFAOYSA-N 0.000 claims 1
- RDPOMKKCZGEBLD-UHFFFAOYSA-N n-methyl-n-[[1-(pyridin-4-ylmethyl)benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC1=CC=NC=C1 RDPOMKKCZGEBLD-UHFFFAOYSA-N 0.000 claims 1
- IQXQWHXZHHNBDM-UHFFFAOYSA-N n-methyl-n-[[1-[(4-methylmorpholin-2-yl)methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC1CN(C)CCO1 IQXQWHXZHHNBDM-UHFFFAOYSA-N 0.000 claims 1
- FEHKLDRBMKRELY-UHFFFAOYSA-N n-methyl-n-[[1-[2-(1-methylimidazol-4-yl)ethyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCC1=CN(C)C=N1 FEHKLDRBMKRELY-UHFFFAOYSA-N 0.000 claims 1
- IEIXJEORNZDGHV-UHFFFAOYSA-N n-methyl-n-[[1-[2-(3-methylimidazol-4-yl)ethyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCC1=CN=CN1C IEIXJEORNZDGHV-UHFFFAOYSA-N 0.000 claims 1
- ZPPFIEZIZKYHFC-UHFFFAOYSA-N n-methyl-n-[[1-[3-(pyridin-2-ylmethylamino)propyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CCCNCC1=CC=CC=N1 ZPPFIEZIZKYHFC-UHFFFAOYSA-N 0.000 claims 1
- SLDUKYQEMGDZLU-UHFFFAOYSA-N n-methyl-n-[[1-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]benzimidazol-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1N(C)CC1=NC2=CC=CC=C2N1CC(C=C1)=CC=C1CNCC1=CC=CC=N1 SLDUKYQEMGDZLU-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- RGHNJXZEOKUKBD-NRXMZTRTSA-N (2r,3r,4r,5s)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-NRXMZTRTSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- NLJDBTZLVTWXRG-UHFFFAOYSA-N tert-butylazanium;iodide Chemical compound [I-].CC(C)(C)[NH3+] NLJDBTZLVTWXRG-UHFFFAOYSA-N 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59803004P | 2004-08-02 | 2004-08-02 | |
| PCT/US2005/026797 WO2006020415A1 (en) | 2004-08-02 | 2005-07-29 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508357A JP2008508357A (ja) | 2008-03-21 |
| JP2008508357A5 true JP2008508357A5 (enExample) | 2008-09-18 |
Family
ID=35907732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007524853A Pending JP2008508357A (ja) | 2004-08-02 | 2005-07-29 | 化学的化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080096861A1 (enExample) |
| EP (1) | EP1778231A4 (enExample) |
| JP (1) | JP2008508357A (enExample) |
| CA (1) | CA2575560A1 (enExample) |
| MX (1) | MX2007001514A (enExample) |
| TW (1) | TW200612935A (enExample) |
| WO (1) | WO2006020415A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2427989T3 (es) | 2005-10-28 | 2013-11-05 | Ono Pharmaceutical Co., Ltd. | Compuesto que contiene un grupo básico y uso del mismo |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
| WO2008016006A1 (fr) | 2006-07-31 | 2008-02-07 | Ono Pharmaceutical Co., Ltd. | Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation |
| US8586748B2 (en) * | 2008-04-09 | 2013-11-19 | Boehringer Ingelheim International Gmbh | 2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10 |
| WO2012075362A2 (en) | 2010-12-03 | 2012-06-07 | Emory University | Chemokine cxcr4 receptor modulators and used related thereto |
| CA2820078C (en) | 2010-12-16 | 2019-02-12 | F. Hoffmann-La Roche Ag | Tricyclic pi3k inhibitor compounds and methods of use |
| JP5766820B2 (ja) | 2011-02-09 | 2015-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｐｉ３キナーゼ阻害剤としての複素環化合物 |
| US10450293B2 (en) | 2014-05-16 | 2019-10-22 | Emory University | Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto |
| CN104447567B (zh) * | 2014-11-02 | 2016-06-29 | 湖南华腾制药有限公司 | 一种1位取代苯并咪唑衍生物的制备方法 |
| US11357742B2 (en) | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2907489T3 (es) | 2015-12-14 | 2022-04-25 | X4 Pharmaceuticals Inc | Métodos para el tratamiento del cáncer |
| ES2935834T3 (es) | 2015-12-22 | 2023-03-10 | X4 Pharmaceuticals Inc | Métodos para tratar enfermedad de inmunodeficiencia |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3471716A1 (en) | 2016-06-16 | 2019-04-24 | Centre National De La Recherche Scientifique | Cxcr4 receptor-binding compounds useful for increasing interferon level |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| AU2018225556A1 (en) | 2017-02-21 | 2019-10-03 | Emory University | Chemokine CXCR4 receptor modulators and uses related thereto |
| WO2019183133A1 (en) | 2018-03-19 | 2019-09-26 | Emory University | Pan-Tropic Entry Inhibitors |
| CN108373466B (zh) * | 2018-04-16 | 2020-04-10 | 宏冠生物药业有限公司 | 一种达比加群酯的制备方法 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2021183650A1 (en) | 2020-03-10 | 2021-09-16 | X4 Pharmaceuticals, Inc. | Methods for treating neutropenia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60039978D1 (de) * | 1999-04-26 | 2008-10-02 | Edwards Lifesciences Ag | Substitutions-infusionflüssigkeit und zitratanticoagulation |
| DE60137435D1 (de) * | 2000-09-15 | 2009-03-05 | Anormed Inc | Chemokin rezeptor bindenden heterozyklische verbindungen |
| JP2004512336A (ja) * | 2000-09-15 | 2004-04-22 | アノーメッド インコーポレイティド | ケモカインレセプター結合複素環式化合物 |
| HUP0302960A3 (en) * | 2000-09-15 | 2007-03-28 | Anormed Inc | Chemokine receptor binding heterocyclic compounds, their use and pharmaceutical compositions contining them |
| BRPI0215050B8 (pt) * | 2001-12-21 | 2021-05-25 | Anormed Inc | compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem |
| US6743194B2 (en) * | 2002-03-28 | 2004-06-01 | Igal Sharon | Multi-compartment syringe |
-
2005
- 2005-07-29 WO PCT/US2005/026797 patent/WO2006020415A1/en not_active Ceased
- 2005-07-29 EP EP05776484A patent/EP1778231A4/en not_active Withdrawn
- 2005-07-29 JP JP2007524853A patent/JP2008508357A/ja active Pending
- 2005-07-29 US US11/573,116 patent/US20080096861A1/en not_active Abandoned
- 2005-07-29 MX MX2007001514A patent/MX2007001514A/es not_active Application Discontinuation
- 2005-07-29 CA CA002575560A patent/CA2575560A1/en not_active Abandoned
- 2005-07-29 TW TW094125858A patent/TW200612935A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008508357A5 (enExample) | ||
| RU2351588C2 (ru) | Производные n-фенил(пиперидин-2-ил)метил-бензамида и их применение в терапии | |
| JP2017128605A (ja) | 抗ウイルス化合物の固体形態 | |
| AU2013365742B2 (en) | Autotaxin inhibitors | |
| JP6045495B2 (ja) | 眼圧を低下させるための［３−（１−（１ｈ−イミダゾール−４−イル）エチル）−２−メチルフェニル］メタノールのエステル・プロドラッグ | |
| TWI540133B (zh) | 嘧啶衍生物之製造方法 | |
| JP2019069948A (ja) | 肺疾患の治療のための高浸透性プロドラッグ組成物およびその薬学的組成物 | |
| CZ83096A3 (en) | Piperidine derivatives, process of their preparation and pharmaceutical composition containing thereof | |
| JP2010513458A (ja) | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用 | |
| JP6218940B2 (ja) | キニン系化合物、その光学異性体及びその製造方法と医薬用途 | |
| EP1499589A1 (fr) | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
| HUE029485T2 (en) | New cyclohexylamine derivatives with B2 adrenergic agonist and M3 muscarinic antagonist activity | |
| WO2017040606A1 (en) | Isoxazole derivatives for use in the treatment of pulmonary diseases and disorders | |
| KR20040039495A (ko) | 신규 4-(2-푸로일)아미노피페리딘, 그의 합성 중간체,그의 제조방법 및 의약으로서의 그의 용도 | |
| CN103833713A (zh) | 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途 | |
| JP2009503048A (ja) | 尿路機能障害を治療するためのｍｃ４ｒ作動薬 | |
| TW201103911A (en) | Novel fumarate salts of a histamine H3 receptor antagonist | |
| KR20010031839A (ko) | 한 개의 질소원자를 함유하는 5, 6 또는 7원헤테로사이클릭 환으로 치환된 이미다조일알킬 | |
| KR20010031724A (ko) | 페닐-알킬-이미다졸 유형의 ｈ₃ 수용체 리간드 | |
| CN103237790B (zh) | 新型甲基环己烷衍生物及其用途 | |
| JP2009517483A (ja) | 一酸化窒素シンターゼの二量化の抑制剤としてのイミダゾール誘導体 | |
| JPWO2010032731A1 (ja) | 結晶態様のベンゾイミダゾール化合物又はその塩 | |
| CN107304180B (zh) | 苯甲酰胺类衍生物、其制备方法及其在医药上的用途 | |
| TW202430512A (zh) | 類木瓜蛋白酶(PLpro)抑制劑 | |
| TW200410922A (en) | Muscarinic agonists |